Shares of Eli Lilly (LLY) are moving lower after Novo Nordisk (NVO) announced plans to cut the U.S. list prices for its weight loss drug Wegovy and Ozempic next year by as much as 50%. Novo announced a monthly price of $675 across the board for its semaglutide drugs. Lilly’s competing obesity drug Zepbound currently has a list price of $1,086.37, according to Bloomberg. Shares of Eli Lilly are down 3%, or $33.97, to $1,024.53 in early trading.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo Nordisk Stock (NVO) Sinks Further on Wegovy and Ozempic Price Cut Plan
- Novo Nordisk to reduce Ozempic, Wegovy list prices by up to 50%, WSJ reports
- Eli Lilly: Conservative 2026 Guide, Diversified Pipeline, and Capital Flexibility Underscore Buy Rating Amid Obesity Leadership
- Eli Lilly call volume above normal and directionally bullish
- Magnifique! U.S. Chess Champion’s Healthiest 2026 Move – French Biotech Abivax (ABVX)